We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

81 hedge funds and large institutions have $660M invested in Audentes Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

61% more capital invested

Capital invested by funds: $409M → $660M (+$251M)

16% more funds holding

Funds holding: 70 → 81 (+11)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
81
Holders Change
+11
Holders Change %
+15.71%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
24
Reduced
23
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$64.1M
2
AG
Artal Group
Luxembourg
+$4.34M
3
AC
Ascend Capital
California
+$3.3M
4
Morgan Stanley
Morgan Stanley
New York
+$2.88M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$14.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.13M
3
BlackRock
BlackRock
New York
-$5.06M
4
DM
Deerfield Management
New York
-$4.43M
5
RG
Redmile Group
California
-$3.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$459K – – –
Deutsche Bank
52
Deutsche Bank
Germany
$431K -$100K -4,608 -23%
VF
53
Virtu Financial
New York
$429K +$332K +15,309 New
Goldman Sachs
54
Goldman Sachs
New York
$420K +$1.87K +86 +0.6%
Wells Fargo
55
Wells Fargo
California
$404K +$145K +6,667 +86%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$374K +$3.69K +170 +1%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$355K -$19.7K -907 -7%
CS
58
Credit Suisse
Switzerland
$341K +$265K +12,190 New
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$322K – – –
State of Wisconsin Investment Board
60
State of Wisconsin Investment Board
Wisconsin
$308K – – –
TI
61
Trexquant Investment
Connecticut
$295K +$229K +10,536 New
AIG
62
American International Group
New York
$287K +$16.6K +765 +8%
PCM
63
Prelude Capital Management
New York
$285K +$221K +10,180 New
NFA
64
Nationwide Fund Advisors
Ohio
$241K – – –
BBP
65
Banco BTG Pactual
Brazil
$234K +$182K +8,368 New
UBS Group
66
UBS Group
Switzerland
$219K +$157K +7,219 +1,209%
SG Americas Securities
67
SG Americas Securities
New York
$143K +$111K +5,094 New
Legal & General Group
68
Legal & General Group
United Kingdom
$134K +$10.3K +476 +11%
Barclays
69
Barclays
United Kingdom
$114K +$72.1K +3,322 +436%
TRCT
70
Tower Research Capital (TRC)
New York
$84K +$62.6K +2,881 +2,770%
AI
71
ArchPoint Investors
Florida
$84K +$65.1K +3,000 New
SO
72
STRS Ohio
Ohio
$50K – – –
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$40K +$29.6K +1,365 +2,528%
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$37.6K -$5.88K -271 -17%
AIP
75
Ameritas Investment Partners
Nebraska
$28K – – –
1 2
3
4

BOLD Hedge Fund Activity: Q3 2017 in Review

81 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2017, worth a combined $660M — up 61% from $409M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BOLD positions and 6 closed out — a net gain of 12 holders — while 24 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $64.1M. The largest seller was OrbiMed, cutting an estimated $14.6M.

  • 81 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $660M of Audentes Therapeutics, Inc stock for Q3 2017, up 61% quarter-over-quarter.
  • 18 funds opened new Audentes Therapeutics, Inc positions in Q3 2017 and 6 closed out, a net change of +12 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $64.1M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2017 was OrbiMed, an estimated $14.6M sold.

Based on aggregated 13F filings for Q3 2017.